Tonix Pharmaceuticals Holding (TNXP) Stock Overview
A fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TNXP Community Fair Values
Create NarrativeSee what 71 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Tonix Pharmaceuticals Holding Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.24 |
| 52 Week High | US$69.97 |
| 52 Week Low | US$13.07 |
| Beta | 1.86 |
| 1 Month Change | -12.55% |
| 3 Month Change | -29.80% |
| 1 Year Change | -11.73% |
| 3 Year Change | -99.89% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Shareholder Returns
| TNXP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.6% | -1.0% | -1.6% |
| 1Y | -11.7% | 23.6% | 17.6% |
Return vs Industry: TNXP underperformed the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: TNXP underperformed the US Market which returned 17.6% over the past year.
Price Volatility
| TNXP volatility | |
|---|---|
| TNXP Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TNXP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TNXP's weekly volatility has decreased from 16% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 142 | Seth Lederman | www.tonixpharma.com |
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Tonix Pharmaceuticals Holding Corp. Fundamentals Summary
| TNXP fundamental statistics | |
|---|---|
| Market cap | US$177.49m |
| Earnings (TTM) | -US$124.02m |
| Revenue (TTM) | US$13.11m |
Is TNXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNXP income statement (TTM) | |
|---|---|
| Revenue | US$13.11m |
| Cost of Revenue | US$6.64m |
| Gross Profit | US$6.47m |
| Other Expenses | US$130.49m |
| Earnings | -US$124.02m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.25 |
| Gross Margin | 49.34% |
| Net Profit Margin | -946.22% |
| Debt/Equity Ratio | 0% |
How did TNXP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/15 15:38 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tonix Pharmaceuticals Holding Corp. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Chiara Russo | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |